Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Electromed, Inc. (ELMD) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of $0.26 per share. This compares to earnings of $0.21 per share a year ago.

Electromed, Inc. (ELMD) Q3 2026 Earnings Call Transcript

NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. Announces Record Financial Performance in Fiscal 2026 Third Quarter.

NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. to Report Q3 Fiscal 2026 Financial Results on May 12, 2026.

Electromed (ELMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Electromed (ELMD) has delivered strong revenue growth and margin improvement, but faces a highly competitive, fragmented market for its SmartVest product. ELMD lacks a durable moat, with rivals like Tactile Medical and Baxter showing stronger brand recognition, technological advantages, and higher recent growth rates. Scientific evidence questions the comparative efficacy of HFCWO versus alternative airway clearance therapies, undermining the long-term growth thesis for SmartVest.

ISRG, EW and ELMD tap GenAI to enhance diagnostics and workflows, even as MedTech faces cost pressures, data risks and macro headwinds.